AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,424.00p
   
  • Change Today:
    228.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,725.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.61m
  • Volume: 590,704
  • Market Cap: £177,141m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.1% 0.0%
Div Cover 2.6 2.7
Op Mrgn 18.5% 31.3%
ROCE 60.7%  
Latest F'cast
P/E 17.7 15.6
PEG 1.3 1.2
Pr/Revenue 4.2 3.2
Pr/Book 5.5  
Latest F'cast
Revenue 18.0% -18.3%
PBT 26.0% 59.2%
EPS 13.1% 9.0%
DPS 6.9% -37.2%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 26,617.00 3,916.00 244.00¢ 38.9 0.3 +137% 280.00¢ 3.0%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,404.5 n/a -97% 287.00¢ 2.6%
31-Dec-22 44,351.00 2,501.00 212.00¢ 68.5 0.0 +2,550% 290.00¢ 2.0%
31-Dec-23 45,811.00 6,899.00 726.00¢ 18.9 0.1 +242% 290.00¢ 2.1%
31-Dec-24 54,073.00 8,691.00 821.00¢ 16.5 1.3 +13% 310.00¢ 2.3%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 57,165.34 17,919.87 692.26p 16.2 1.8 +9% 252.07p 0.0%
31-Dec-26 60,619.09 20,015.11 784.02p 14.3 1.1 +13% 264.26p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

AZN invests $2.5bn in Beijing R&D & manufacturing 21-Mar-2025 10:58 RNS
Eneboparatide Phase III trial met primary endpoint 17-Mar-2025 07:10 RNS
Imfinzi approved in EU for limited-stage SCLC 17-Mar-2025 07:05 RNS

AstraZeneca ShareCast News

AstraZeneca spending $2.5bn on new R&D centre, b... 21-Mar-2025 ShareCast
AstraZeneca buys biotech firm Esobiotec for up t... 17-Mar-2025 ShareCast
AstraZeneca hails trial results for imfinzi on g... 07-Mar-2025 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca scrapped £450m plant after governmen... 19-Mar-2025 Times
Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
06-Mar-25 Transfer From Pascal Soriot 0.000p 89,962 £0.00
05-Mar-25 Buy Dividends Aradhana Sarin 0.000p 28 £0.00
05-Mar-25 Buy Dividends Pascal Soriot 0.000p 248 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,424.00p
Change Today 228.00p
% Change 2.04 %
52 Week High 13,276.00
52 Week Low 9,725.00
Volume 590,704
Shares Issued 1,550.61m
Market Cap £177,141m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.05% below the market average93.05% below the market average93.05% below the market average93.05% below the market average93.05% below the market average
78.72% below the sector average78.72% below the sector average78.72% below the sector average78.72% below the sector average78.72% below the sector average
Price Trend
14.92% above the market average14.92% above the market average14.92% above the market average14.92% above the market average14.92% above the market average
38.78% above the sector average38.78% above the sector average38.78% above the sector average38.78% above the sector average38.78% above the sector average
Income
65.31% below the market average65.31% below the market average65.31% below the market average65.31% below the market average65.31% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
85.37% above the market average85.37% above the market average85.37% above the market average85.37% above the market average85.37% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 15
Neutral 4
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 28-Mar-2025

Time Volume / Share Price
16:00 0 @ 11,428.00p
16:00 191 @ 11,424.00p
16:00 9 @ 11,424.00p
16:00 41 @ 11,426.00p
16:00 49 @ 11,426.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page